Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 3/20 | 0.50 |
| ▸ | KCNA3 | P22001 | 2/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | PDE4A | P27815 | 1/20 | 0.50 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.50 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.50 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.50 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | CA9 | Q16790 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30375567 | 1.00 | MAOB (0.50) | MAOBKCNA3LMNAHPGDPDE4A | |
| SCHEMBL8052928 | 0.91 | MAPT (0.50) | MAOBKCNA3LMNAHPGDMAPT | |
| SCHEMBL21217354 | 0.88 | PDE4A (0.57) | KCNA3HPGDPDE4APDE4BPDE4C | |
| SCHEMBL29855379 | 0.85 | MAPT (0.52) | MAOBKCNA3LMNAHPGDPTPN1 | |
| SCHEMBL30789227 | 0.80 | MAOB (0.56) | MAOBLMNAHPGDMAPTCYP2C9 | |
| SCHEMBL14616693 | 0.80 | MAOB (0.56) | MAOBLMNAHPGDMAPTCYP2C9 | |
| SCHEMBL14178903 | 0.80 | CYP3A4 (0.63) | MAOBLMNAHPGDMAPTSMN1; SMN2 | |
| SCHEMBL17536648 | 0.79 | CYP19A1 (0.55) | LMNAPDE4APDE4BPDE4CPDE4D | |
| SCHEMBL658101 | 0.79 | MAOB (0.61) | MAOBLMNAMAPTCYP2C9CYP2C19 | |
| SCHEMBL30141054 | 0.79 | MAOB (0.61) | MAOBLMNAMAPTCYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160060241-A1 | COMPOUNDS FOR TREATMENT OF ANGIOGENESIS-MEDIATED DISEASES | GACHON UNIVERSITY OF INDUSTRY-ACADEMIC COOPERATION FOUNDATION (KR) | 2016-03-03 | — | — | US | claimed |
| EP-2994460-B1 | COMPOUNDS FOR TREATMENT OF ANGIOGENESIS-MEDIATED DISEASES | UNIV INDIANA RES & TECH CORP (US) | 2024-12-04 | — | — | EP | disclosed |
| CN-111836808-B | Novel compound for preventing, alleviating or treating fibrosis or nonalcoholic steatohepatitis and composition comprising the same as active ingredient | 欧斯特奥纽罗根有限公司 | 2023-04-28 | — | — | CN | disclosed |
| EP-3760626-B1 | NOVEL COMPOUND AND COMPOSITION FOR PREVENTING, AMELIORATING, OR TREATING FIBROSIS OR NONALCOHOLIC STEATOHEPATITIS COMPRISING SAME AS ACTIVE INGREDIENT | OSTEONEUROGEN INC (KR) | 2022-05-18 | — | — | EP | disclosed |
| EP-3760626-A1 | NOVEL COMPOUND AND COMPOSITION FOR PREVENTING, AMELIORATING, OR TREATING FIBROSIS OR NONALCOHOLIC STEATOHEPATITIS COMPRISING SAME AS ACTIVE INGREDIENT | Osteoneurogen Inc. (KR) | 2021-01-06 | — | — | EP | disclosed |
| CN-111836808-A | Novel compound for preventing, alleviating or treating fibrosis or nonalcoholic steatohepatitis and composition comprising same as active ingredient | 欧斯特奥纽罗根有限公司 | 2020-10-27 | — | — | CN | disclosed |
| US-10738024-B2 | Compounds for treatment of angiogenesis-mediated diseases | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2020-08-11 | — | — | US | disclosed |
| US-20190263789-A1 | SUBSTITUTED CHROMENES FOR TREATMENT OF FIBROSIS OR NON-ALCOHOLIC STEATOHEPATITIS | OSTEONEUROGEN INC. (KR) | 2019-08-29 | — | — | US | disclosed |
| US-10370364-B1 | Substituted chromenes for treatment of fibrosis or non-alcoholic steatohepatitis | OSTEONEUROGEN INC. (KR) | 2019-08-06 | — | — | US | disclosed |
| US-10238627-B2 | Compounds for treatment of angiogenesis-mediated diseases | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2019-03-26 | — | — | US | disclosed |
| US-20180177758-A1 | COMPOUNDS FOR TREATMENT OF ANGIOGENESIS-MEDIATED DISEASES | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION | 2018-06-28 | — | — | US | disclosed |
| WO-2017146332-A1 | NOVEL USE OF CHROMONE DERIVATIVE AS PHARMACEUTICAL COMPOSITION FOR PREVENTING AND TREATING FIBROSIS BY USING EPITHELIAL-MESENCHYMAL TRANSITION INHIBITORY ACTIVITY THEREOF | (주)오스티오뉴로젠 | 2017-08-31 | — | — | WO | disclosed |
| US-20170239211-A1 | USE OF CHROMONE DERIVATIVE AS PHARMACEUTICAL COMPOSITION FOR PREVENTION AND TREATMENT OF FIBROSIS USING EMT INHIBITORY ACTIVITY | OSTEONEUROGEN INC. (KR) | 2017-08-24 | — | — | US | disclosed |
| EP-2994460-A1 | COMPOUNDS FOR TREATMENT OF ANGIOGENESIS-MEDIATED DISEASES | Indiana University Research and Technology Corporation (US) | 2016-03-16 | — | — | EP | disclosed |
| US-20160060241-A1 | COMPOUNDS FOR TREATMENT OF ANGIOGENESIS-MEDIATED DISEASES | GACHON UNIVERSITY OF INDUSTRY-ACADEMIC COOPERATION FOUNDATION (KR) | 2016-03-03 | — | — | US | disclosed |
| WO-2014182695-A1 | COMPOUNDS FOR TREATMENT OF ANGIOGENESIS-MEDIATED DISEASES | INDIANA UNIVERSITY RESEARCH & TECHNOLOGY CORPORATION (US) | 2014-11-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10370364-B1 | Substituted chromenes for treatment of fibrosis or non-alcoholic steatohepatitis | CYP7A1, NR1H3, CES1 | MAOB 838/4885KCNA3 3138/4885LMNA 2458/4885 |
| US-20190263789-A1 | SUBSTITUTED CHROMENES FOR TREATMENT OF FIBROSIS OR NON-ALCOHOLIC STEATOHEPATITIS | VIM, HNF4A, CDH1 | MAOB 3006/4885KCNA3 4277/4885LMNA 1189/4885 |
| US-10738024-B2 | Compounds for treatment of angiogenesis-mediated diseases | KDR, TEK, VEGFA | MAOB 1469/4885KCNA3 4778/4885LMNA 4429/4885 |
| US-20180177758-A1 | COMPOUNDS FOR TREATMENT OF ANGIOGENESIS-MEDIATED DISEASES | KDR, TEK, VEGFA | MAOB 1469/4885KCNA3 4778/4885LMNA 4429/4885 |
| US-20160060241-A1 | COMPOUNDS FOR TREATMENT OF ANGIOGENESIS-MEDIATED DISEASES | KDR, TEK, VEGFA | MAOB 1469/4885KCNA3 4778/4885LMNA 4429/4885 |
| US-10238627-B2 | Compounds for treatment of angiogenesis-mediated diseases | KDR, TEK, VEGFA | MAOB 1469/4885KCNA3 4778/4885LMNA 4429/4885 |
| US-20170239211-A1 | USE OF CHROMONE DERIVATIVE AS PHARMACEUTICAL COMPOSITION FOR PREVENTION AND TREATMENT OF FIBROSIS USING EMT INHIBITORY ACTIVITY | CDH1, SMAD3, SMAD2 | MAOB 3811/4885KCNA3 4426/4885LMNA 2614/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.